EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

d -Amphetamine Transdermal System in Treatment of Children and Adolescents With ADHD: SKAMP Subscale Analysis and Subgroup Analysis from a Pivotal Trial

Andrew J Cutler iD, Marina Komaroff, Mariacristina Castelli, Suzanne Meeves, Mahwish Khan

Journal of Child and Adolescent Psychopharmacology · 01.05.2026 · 36 (4) · 193-199

DOI: 10.1177/10445463261434530 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Child and Adolescent Psychopharmacology, online erschienen am 02.04.2026. Verfasst von Andrew J Cutler und 4 weiteren Autor:innen. Beteiligte Einrichtung: SUNY Upstate Medical University and Neuroscience Education Institute, Lakewood Ranch, Florida, USA. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Central Nervous System Stimulants, Dextroamphetamine. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Noven Pharmaceuticals, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives: d -Amphetamine transdermal system ( d -ATS) is FDA-approved for treating attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients ≥6 years. In a pivotal study, d -ATS met its primary (SKAMP total score) and secondary endpoints. This analysis further evaluated d -ATS efficacy using SKAMP subscale scores and total score by subgroup.

Methods

The pivotal study comprised a 5-week, open-label dose-optimization period (DOP) followed by a 2-week, randomized, cross-over double-blind treatment period (DBP). All eligible patients received d -ATS 5 mg/9 h, with weekly evaluation for dose increase and the optimal dose maintained during the DBP. Preplanned subgroup analyses of mean SKAMP total score in the DBP by optimized dose, sex, age group, ADHD type, and baseline ADHD severity were conducted. Efficacy was assessed by difference ( d -ATS vs. placebo) in least-squares (LS) mean SKAMP total and subscale scores (Attention, Deportment, and Quality of Work) from a mixed-model repeated-measures (MMRM) analysis and is reported throughout as LS mean (95% confidence interval [CI]). Model-based effect sizes were calculated post hoc .

Results

In total, 110 patients were enrolled in the DOP; 106 were randomized in the DBP. The LS mean difference in SKAMP total score of d -ATS versus placebo was −5.9 (−6.8, −5.0), with differences in subscale scores (Attention, Deportment, and Quality of Work) of −1.4 (−1.7, −1.1), −1.9 (−2.2, −1.5), and −1.3 (−1.5, −1.0), respectively. Model-based effect sizes were 0.57, 0.42, 0.43, and 0.47, respectively. Patients receiving d -ATS demonstrated improvements versus placebo in LS mean SKAMP total score at each optimized dose in both male and female patients and children and adolescents and regardless of ADHD subtype or baseline ADHD severity.

Conclusions

Consistent efficacy of d -ATS across subgroups and all SKAMP subscale scores suggests broad utility of d -ATS in all patients, regardless of age, sex, ADHD type, or baseline ADHD severity, and broad applicability of these results to patients with varying clinical presentations of functional impairment by ADHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsDextroamphetamineHumansChildDouble-Blind MethodFemaleMaleAdolescentCross-Over StudiesAdministration, CutaneousDose-Response Relationship, DrugTreatment OutcomeSeverity of Illness Index

Stichwörter der Autor:innen

ADHDSKAMPd-ATSsubgroupsubscale

Substanzen

Central Nervous System StimulantsDextroamphetamine

Autor:innen und Institutionen

  • SUNY Upstate Medical University and Neuroscience Education Institute, Lakewood Ranch, Florida, USA.
  • Product Development, Noven Pharmaceuticals, Inc., Jersey City, New Jersy, USA.

ORCID-Profile: Andrew J Cutler

Förderung

  • Noven Pharmaceuticals, Inc.

Zitieren

APA

Cutler, A. J., Komaroff, M., Castelli, M., Meeves, S., & Khan, M. (2026). d -Amphetamine Transdermal System in Treatment of Children and Adolescents With ADHD: SKAMP Subscale Analysis and Subgroup Analysis from a Pivotal Trial. Journal of Child and Adolescent Psychopharmacology, 36(4), 193-199. https://doi.org/10.1177/10445463261434530

Vancouver

Cutler AJ, Komaroff M, Castelli M, Meeves S, Khan M. d -Amphetamine Transdermal System in Treatment of Children and Adolescents With ADHD: SKAMP Subscale Analysis and Subgroup Analysis from a Pivotal Trial. Journal of Child and Adolescent Psychopharmacology. 2026;36(4):193-199. doi:10.1177/10445463261434530

BibTeX
@article{Cutler2026,
  author = {Cutler, Andrew J and Komaroff, Marina and Castelli, Mariacristina and Meeves, Suzanne and Khan, Mahwish},
  title = {d -Amphetamine Transdermal System in Treatment of Children and Adolescents With ADHD: SKAMP Subscale Analysis and Subgroup Analysis from a Pivotal Trial},
  journal = {Journal of Child and Adolescent Psychopharmacology},
  year = {2026},
  volume = {36},
  number = {4},
  pages = {193--199},
  doi = {10.1177/10445463261434530}
}
Kostenlos starten →